What is the dosing range for Dulaglutide?

Dulaglutide is typically dosed at 0.75mg (low), 1.5mg (moderate), or 4.5mg (high) mg, administered once weekly subcutaneous. These ranges are aggregated from preclinical research and community protocols — not medical dosing guidance.

What are the reported side effects of Dulaglutide?

Reported side effects of Dulaglutide include: Nausea (most common), Diarrhea, Vomiting, Abdominal pain, Decreased appetite, Injection site reactions, Rare pancreatitis, Thyroid C-cell concerns, Tachycardia (mild, transient).

GLP-1

Dulaglutide

Also known as: Trulicity, LY2189265

Share:Share on Reddit

Dulaglutide (Trulicity) is an FDA-approved prescription medication. This profile is for research and educational context only.

📚 Content aggregated from:2 peer-reviewed sources·r/Peptides community·PubMed / NCBI

Overview

Once-weekly GLP-1 receptor agonist (Trulicity) approved for type 2 diabetes and cardiovascular risk reduction. Engineered as a GLP-1 analogue fused to a modified IgG4-Fc domain, which provides a ~5-day half-life and enables once-weekly subcutaneous dosing via a simple auto-injector pen with no reconstitution required.

Research Summary

Dulaglutide's large molecular structure (fusion with IgG4-Fc) prevents renal filtration and extends half-life via FcRn recycling, enabling once-weekly dosing. The REWIND cardiovascular outcomes trial demonstrated significant reduction in major adverse cardiovascular events (MACE) in patients with or at risk for cardiovascular disease, establishing dulaglutide as a cardioprotective agent beyond glucose control.

Dosing Range

low

0.75mg

moderate

1.5mg

high

4.5mg

Units: mg · Frequency: once weekly subcutaneous

Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.

Administration Routes

Subcutaneous injection (auto-injector pen)

Reconstitution Notes

Single-dose auto-injector pen for clinical use — no reconstitution required. Research lyophilized formulation: reconstitute per manufacturer protocol with supplied diluent. Store pens at 2–8°C.

Step-by-step reconstitution guide →

Supplies you'll need

Insulin Syringes (U-100)Reconstitution Needles Lambda BAC Water Alcohol Prep Pads

Affiliate links — Research Stack may earn a small commission at no extra cost to you.

Reported Side Effects

Nausea (most common)
Diarrhea
Vomiting
Abdominal pain
Decreased appetite
Injection site reactions
Rare pancreatitis
Thyroid C-cell concerns
Tachycardia (mild, transient)

Research Papers

2 peer-reviewed sources

Dulaglutide and cardiovascular outcomes in type 2 diabetes: REWIND trial

The Lancet2020

Efficacy and safety of dulaglutide versus sitagliptin in T2D: AWARD-5 trial

Diabetes Care2015

Community Experiences

Aggregated from public forums. Anecdotal — not clinical evidence.

r/diabetes_t2

Community reports on Trulicity injection experience, nausea management, and comparison to semaglutide.

View original thread

r/GLP1

GLP-1 user community discussing dulaglutide vs. semaglutide for weight loss and tolerability.

View original thread

Overview

Dulaglutide (Trulicity) is an injectable GLP-1 receptor agonist developed by Eli Lilly and approved by the FDA in 2014. Its molecular engineering represents a major advance in long-acting GLP-1 pharmacology: rather than modifying the GLP-1 peptide itself (as liraglutide and semaglutide do with fatty acid conjugation), dulaglutide fuses a modified GLP-1 sequence directly to the Fc region of immunoglobulin G4.

This creates a large protein (~59 kDa) that cannot be filtered by the kidney and is recycled by the FcRn receptor system — the same mechanism that extends the half-life of antibodies. The result is a half-life of approximately 5 days, enabling once-weekly dosing.

Mechanism

GLP-1 Receptor Activation

Like all GLP-1 receptor agonists, dulaglutide activates GLP-1R on:

Beta cells (insulin secretion — glucose-dependent)
Alpha cells (glucagon suppression)
GI tract (gastric emptying delay)
Hypothalamus (appetite suppression)
Cardiovascular system (direct protective effects)

Half-Life Extension via IgG4-Fc Fusion

The IgG4-Fc fusion:

Creates a large molecule (~59 kDa) that exceeds the renal filtration threshold
Enables FcRn-mediated recycling (endosomal pH-dependent — absorbed, released back into circulation)
Modified IgG4 hinge reduces Fc effector function (minimizing immune activation)

REWIND Trial: Cardiovascular Evidence

The REWIND (Researching Cardiovascular Events With a Weekly INcretin in Diabetes) trial was distinctive among GLP-1 cardiovascular outcomes trials:

Primary outcome: 3-point MACE (CV death, non-fatal MI, non-fatal stroke)
Population: T2D patients with heterogeneous CV risk — ~69% had established CV disease, ~31% did not
Result: 12% relative risk reduction in MACE (HR 0.88, 95% CI 0.79–0.99)
Notable: The benefit extended to patients without established CV disease, unlike some other GLP-1 trials that required established CVD for enrollment

Comparison: Once-Weekly GLP-1 Agents

| Parameter | Dulaglutide | Semaglutide SC | Exenatide ER | |-----------|-------------|----------------|--------------| | Brand | Trulicity | Ozempic | Bydureon | | Dose | 0.75–4.5mg | 0.25–2.0mg | 2mg | | HbA1c reduction | ~1.0–1.5% | ~1.5–2.0% | ~1.0–1.5% | | Weight loss | ~2–4kg | ~5–7kg | ~2–4kg | | MACE reduction | Yes (REWIND) | Yes (SUSTAIN-6) | Neutral (EXSCEL) | | Device | Auto-injector | Pen | Auto-mixer |